Building the New Normal: A Social Democratic Roadmap
Last November 9, American pharmaceutical giant Pfizer announced that its experimental vaccine against COVID-19 has shown significant results, with an efficacy rate of 90%. Though clinical trials are still ongoing, the company's CEO, Dr. Albert Bourla, appeared well-pleased with the development, stating that they are now “a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.” A week later, biotech firm Moderna also reported that its own serum proved 94.5% effective against the deadly disease and that it will soon seek the approval of health regulators in the United States.
These two announcements were made almost a year after the world was first informed about the virus, which has now claimed the lives of more than a million people. The results of the trials were naturally met with a mixture of excitement and relief, raising hopes that the pandemic could soon end, and that people's lives can finally return to normal.